In junk we trust: Repetitive DNA, epigenetics and facioscapulohumeral muscular dystrophy

Epigenomics

Volumn 2, Issue 2, 2010, Pages 271-287

  Neguembor, Maria V ^a,b   Gabellini, Davide ^b,c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c DULBECCO TELETHON INSTITUTE   (Italy)

Author keywords

chromatin; D4Z4 repeat; DNA methylation; epigenetics; facioscapulohumeral muscular dystrophy; FSHD; ncRNA; noncoding RNA; repetitive DNA; transcriptional repression

Indexed keywords

HOMEODOMAIN PROTEIN; NUCLEAR PROTEIN; PROTEIN DUX4; PROTEIN FRG1; REPETITIVE DNA; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DNA METHYLATION; EPIGENETICS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CHROMATIN; CHROMOSOMES, HUMAN, PAIR 4; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MICROSATELLITE REPEATS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; NUCLEAR PROTEINS; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 77954122499     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.8     Document Type: Review

References (100)

1. Taft RJ, Pheasant M, Mattick JS: The relationship between non-protein-coding DNA and eukaryotic complexity. Bioessays 29, 288-299 (2007).
2. Siepel A, Bejerano G, Pedersen JS et al.: Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15, 1034-1050 (2005).
3. Carninci P, Kasukawa T, Katayama S et al.: The transcriptional landscape of the mammalian genome. Science 309, 1559-1563 (2005).
4. Kapranov P, Cheng J, Dike S et al.: RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316, 1484-1488 (2007).
5. Wang ET, Sandberg R, Luo S et al.: Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-476 (2008).
6. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413-1415 (2008).
7. Prasanth K V, Spector DL: Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum. Genes Dev. 21, 11-42 (2007).
8. Kurokawa R, Rosenfeld MG, Glass CK: Transcriptional regulation through noncoding RNAs and epigenetic modifcations. RNA Biol. 6, 233-236 (2009).
9. Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF: RNA regulation of epigenetic processes. Bioessays 31, 51-59 (2009).
10. Faulkner GJ, Carninci P: Altruistic functions for selfsh DNA. Cell Cycle 8, 2895-2900 (2009).
11. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS: Non-coding RNAs: regulators of disease. J. Pathol. 220(2), 126-139 (2009).
12. Pandya S, King WM, Tawil R: Facioscapulohumeral dystrophy. Phys. Ther. 88, 105-113 (2008).
13. Shahrizaila N, Wills AJ: Signifcance of Beevor's sign in facioscapulohumeral dystrophy and other neuromuscular diseases. J. Neurol. Neurosurg. Psychiatry 76, 869-870 (2005).
14. van der Maarel SM, Frants RR, Padberg GW: Facioscapulohumeral muscular dystrophy. Biochim. Biophys. Acta 1772, 186-194 (2007).
15. Tupler R, Gabellini D: Molecular basis of facioscapulohumeral muscular dystrophy. Cell. Mol. Life Sci. 61, 557-566 (2004).
16. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M: Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord. 14, 33-38 (2004).
17. Winokur ST, Barrett K, Martin JH et al.: Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul. Disord. 13, 322-333 (2003).
18. Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, Laoudj-Chenivesse D: Myoblasts from affected and non affected FSHD muscles exhibit morphological differentiation defects. J. Cell. Mol. Med. (2008) (Epub ahead of print).
19. Trevisan CP, Pastorello E, Tomelleri G et al.: Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur. J. Neurol. 15, 1353-1358 (2008).
20. Tawil R, Van Der Maarel SM: Facioscapulohumeral muscular dystrophy. Muscle Nerve 34, 1-15 (2006).
21. Trevisan CP, Pastorello E, Armani M et al.: Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur. Neurol. 56, 1-5 (2006).
22. Galetta F, Franzoni F, Sposito R et al.: Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 15, 403-408 (2005).
23. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW: Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 63, 176-178 (2004). (Pubitemid 38943803)
24. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM: Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch. Phys. Med. Rehabil. 89, 320-328 (2008).
25. Padua L, Aprile I, Frusciante R et al.: Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve 40, 200-205 (2009).
26. de Greef JC, Frants RR, van der Maarel SM: Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat. Res. 647, 94-102 (2008).
27. Rossi M, Ricci E, Colantoni L et al.: The facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure. BMC Med. Genet. 8, 8 (2007).
28. Thomas NS, Wiseman K, Spurlock G, MacDonald M, Ustek D, Upadhyaya M: A large patient study confrming that facioscapulohumeral muscular dystrophy (FSHD) disease expression is almost exclusively associated with an FSHD locus located on a 4qA-defned 4qter subtelomere. J. Med. Genet. 44, 215-218 (2007).
29. Lemmers RJ, Wohlgemuth M, van der Gaag KJ et al.: Specifc sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 81, 884-894 (2007).
30. Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E, van der Maarel SM: Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 75, 1124-1130 (2004).
31. Arashiro P, Eisenberg I, Kho AT et al.: Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared with asymptomatic related carriers. Proc. Natl Acad. Sci. USA 106, 6220-6225 (2009).
32. Bastress KL, Stajich JM, Speer MC, Gilbert JR: The genes encoding for D4Z4-binding proteins HMGB2, YY1, NCL and MYOD1 are excluded as candidate genes for FSHD1B. Neuromuscul. Disord. 15, 316-320 (2005).
33. Tsumagari K, Qi L, Jackson K et al.: Epigenetics of a tandem DNA repeat: chromatin DNaseI sensitivity and opposite methylation changes in cancers. Nucleic Acids Res. 36, 2196-2207 (2008).
34. Jabbari K, Bernardi G: Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene 333, 143-149 (2004).
35. Caiafa P, Zampieri M: DNA methylation and chromatin structure: the puzzling CpG islands. J. Cell. Biochem. 94, 257-265 (2005).
36. Simons C, Pheasant M, Makunin IV, Mattick JS: Transposon-free regions in mammalian genomes. Genome Res. 16, 164-172 (2006).
37. Clapp J, Mitchell LM, Bolland DJ et al.: Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 81, 264-279 (2007).
38. de Greef JC, Lemmers RJ, van Engelen BG et al.: Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum. Mutat. 30, 1449-1459 (2009).
39. van Overveld PG, Enthoven L, Ricci E et al.: Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann. Neurol. 58, 569-576 (2005).
40. de Greef JC, Wohlgemuth M, Chan OA et al.: Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology 69, 1018-1026 (2007).
41. Kim JD, Hinz AK, Bergmann A et al.: Identifcation of clustered YY1 binding sites in imprinting control regions. Genome Res. 16, 901-911 (2006).
42. Ottaviani A, Rival-Gervier S, Boussouar A et al.: The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. PLoS Genet. 5, E1000394 (2009).
43. Ottaviani A, Schluth-Bolard C, Rival-Gervier S et al.: Identifcation of a perinuclear positioning element in human subtelomeres that requires A-type lamins and CTCF. EMBO J. 28, 2428-2436 (2009).
44. Sasai N, Defossez PA: Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes. Int. J. Dev. Biol. 53, 323-334 (2009).
45. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ: How chromatin-binding modules interpret histone modifcations: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025-1040 (2007).
46. Latham JA, Dent SY: Cross-regulation of histone modifcations. Nat. Struct. Mol. Biol. 14, 1017-1024 (2007).
47. Sims RJ 3rd, Reinberg D: Is there a code embedded in proteins that is based on post-translational modifcations? Nat. Rev. Mol. Cell Biol. 9, 815-820 (2008).
48. Bodega B, Ramirez GD, Grasser F et al.: Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biol. 7, 41 (2009).
49. Zeng W, de Greef JC, Chen YY et al.: Specifc loss of histone H3 lysine 9 trimethylation and HP1g/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet. 5, E1000559 (2009).
50. Kwon SH, Workman JL: The heterochromatin protein 1 (HP1) family: put away a bias toward HP1. Mol. Cells 26, 217-227 (2008).
51. Fanti L, Pimpinelli S: HP1: a functionally multifaceted protein. Curr. Opin. Genet. Dev. 18, 169-174 (2008).
52. Dorsett D: Roles of the sister chromatid cohesion apparatus in gene expression, development, and human syndromes. Chromosoma 116, 1-13 (2007).
53. Parelho V, Hadjur S, Spivakov M et al.: Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 132, 422-433 (2008).
54. Hadjur S, Williams LM, Ryan NK et al.: Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus. Nature 460, 410-413 (2009).
55. Gabellini D, Green MR, Tupler R: When enough is enough: genetic diseases associated with transcriptional derepression. Curr. Opin. Genet. Dev. 14, 301-307 (2004).
56. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM: Epigenetic silencing of CCAAT/enhancer-binding protein d activity by YY1/polycomb group/DNA methyltransferase complex. J. Biol. Chem. 283, 30919-30932 (2008).
57. Wu S, Hu YC, Liu H, Shi Y: Loss of YY1 impacts the heterochromatic state and meiotic double-strand breaks during mouse spermatogenesis. Mol. Cell. Biol. 29, 6245-6256 (2009).
58. Kosak ST, Groudine M: Gene order and dynamic domains. Science 306, 644-647 (2004).
59. Kosak ST, Groudine M: Form follows function: the genomic organization of cellular differentiation. Genes Dev. 18, 1371-1384 (2004).
60. Fedorova E, Zink D: Nuclear architecture and gene regulation. Biochim. Biophys. Acta 1783, 2174-2184 (2008).
61. Rajapakse I, Perlman MD, Scalzo D, Kooperberg C, Groudine M, Kosak ST: The emergence of lineage-specifc chromosomal topologies from coordinate gene regulation. Proc. Natl Acad. Sci. USA 106, 6679-6684 (2009).
62. Tam R, Smith KP, Lawrence JB: The 4q subtelomere harboring the FSHD locus is specifcally anchored with peripheral heterochromatin unlike most human telomeres. J. Cell Biol. 167, 269-279 (2004).
63. Masny PS, Bengtsson U, Chung SA et al.: Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease? Hum. Mol. Genet. 13, 1857-1871 (2004).
64. Worman HJ, Fong LG, Muchir A, Young SG: Laminopathies and the long strange trip from basic cell biology to therapy. J. Clin. Invest. 119, 1825-1836 (2009).
65. Gaszner M, Felsenfeld G: Insulators: exploiting transcriptional and epigenetic mechanisms. Nat. Rev. Genet. 7, 703-713 (2006).
66. Filippova GN: Genetics and epigenetics of the multifunctional protein CTCF. Curr. Top. Dev. Biol. 80, 337-360 (2008).
67. Pombo A, Branco MR: Functional organisation of the genome during interphase. Curr. Opin. Genet. Dev. 17, 451-455 (2007).
68. Goetze S, Mateos-Langerak J, van Driel R: Three-dimensional genome organization in interphase and its relation to genome function. Semin. Cell Dev. Biol. 18, 707-714 (2007).
69. Lieberman-Aiden E, van Berkum NL, Williams L et al.: Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289-293 (2009).
70. Petrov A, Allinne J, Pirozhkova I, Laoudj D, Lipinski M, Vassetzky YS: A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy. Genome Res. 18, 39-45 (2008).
71. Pirozhkova I, Petrov A, Dmitriev P, Laoudj D, Lipinski M, Vassetzky Y: A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. PLoS ONE 3, E3389 (2008).
72. Petrov A, Pirozhkova I, Carnac G, Laoudj D, Lipinski M, Vassetzky YS: Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts. Proc. Natl Acad. Sci. USA 103, 6982-6987 (2006).
73. Xu X, Tsumagari K, Sowden J et al.: DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2. Nucleic Acids Res. 37(22), 7381-7393 (2009).
74. Hanel ML, Wuebbles RD, Jones PL: Muscular dystrophy candidate gene FRG1 is critical for muscle development. Dev. Dyn. 238, 1502-1512 (2009).
75. van Koningsbruggen S, Dirks RW, Mommaas AM et al.: FRG1P is localised in the nucleolus, Cajal bodies, and speckles. J. Med. Genet. 41, E46 (2004).
76. Bessonov S, Anokhina M, Will CL, Urlaub H, Luhrmann R: Isolation of an active step I spliceosome and composition of its RNP core. Nature 452, 846-850 (2008).
77. van Koningsbruggen S, Straasheijm KR, Sterrenburg E et al.: FRG1P-mediated aggregation of proteins involved in pre-mRNA processing. Chromosoma 116, 53-64 (2007).
78. Chari A, Paknia E, Fischer U: The role of RNP biogenesis in spinal muscular atrophy. Curr. Opin. Cell Biol. 21, 387-393 (2009).
79. Abu-Baker A, Rouleau GA: Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim. Biophys. Acta 1772, 173-185 (2007).
80. Gabellini D, D'Antona G, Moggio M et al.: Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439, 973-977 (2006).
81. Davidovic L, Sacconi S, Bechara EG et al.: Alteration of expression of muscle specifc isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. J. Med. Genet. 45, 679-685 (2008).
82. Wuebbles RD, Hanel ML, Jones PL: FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Dis. Model. Mech. 2, 267-274 (2009).
83. Lemmers RJ, Osborn M, Haaf T et al.: D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology 61, 178-183 (2003).
84. Winokur ST, Barrett K, Martin JH et al.: Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul. Disord. 13, 322-333 (2003).
85. Jiang G, Yang F, van Overveld PG, Vedanarayanan V, van der Maarel S, Ehrlich M: Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by ana lysis of histone modifcation and gene expression in subtelomeric 4q. Hum. Mol. Genet. 12, 2909-2921 (2003).
86. Masny PS, Chan OY, de Greef JC et al.: Analysis of allele-specifc RNA transcription in FSHD by RNA-DNA FISH in single myonuclei. Eur. J. Hum. Genet. 18(4), 448-456 (2010).
87. Klooster R, Straasheijm K, Shah B et al.: Comprehensive expression ana lysis of FSHD candidate genes at the mRNA and protein level. Eur. J. Hum. Genet. 17, 1615-1624 (2009).
88. Buckingham M, Relaix F: The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu. Rev. Cell Dev. Biol. 23, 645-673 (2007).
89. Dixit M, Ansseau E, Tassin A et al.: DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc. Natl Acad. Sci. USA 104, 18157-18162 (2007).
90. Kowaljow V, Marcowycz A, Ansseau E et al.: The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul. Disord. 17, 611-623 (2007).
91. Bosnakovski D, Lamb S, Simsek T et al.: DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation. Exp. Neurol. (2008) (Epub ahead of print)
92. Ansseau E, Laoudj-Chenivesse D, Marcowycz A et al.: DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation.PLoS ONE 4, E7482 (2009).
93. Lemmers RJ, van der Maarel SM, van Deutekom JC et al.: Inter-and intrachromosomal sub-telomeric rearrangements on 4q35: implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Hum. Mol. Genet. 7, 1207-1214 (1998).
94. Deak KL, Lemmers RJ, Stajich JM et al.: Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4. Neurology 68, 578-582 (2007).
95. Bosnakovski D, Xu Z, Gang EJ et al.: An isogenetic myoblast expression screen identifes DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 27, 2766-2779 (2008).
96. Bosnakovski D, Daughters RS, Xu Z, Slack JM, Kyba M: Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS ONE 4, E7003 (2009).
97. Rowat AC, Lammerding J, Herrmann H, Aebi U: Towards an integrated understanding of the structure and mechanics of the cell nucleus. Bioessays 30, 226-236 (2008).
98. Phillips JE, Corces VG: CTCF: master weaver of the genome. Cell 137, 1194-1211 (2009).
99. Wendt KS, Peters JM: How cohesin and CTCF cooperate in regulating gene expression. Chromosome Res. 17, 201-214 (2009).
100. Cao R, Zhang Y: The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155-164 (2004).